Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00709371 · ClinicalTrials.gov registry record · Phase 2
Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity
A Phase 2 study of Obesity, sponsored by Orexigen Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 729
- Enrollment target
- 20
- Study locations
NCT00709371 is a Phase 2 study of Obesity that has completed, run by Orexigen Therapeutics. The registered enrollment target is 729 participants, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (11% lower). The trial reports 20 study locations across 18 states.
The verdict
NCT00709371, a Phase 2 study of Obesity, has completed, sponsored by Orexigen Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 729 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is determine if the combination of zonisamide SR and bupropion SR are is more effective than either drug given alone or placebo in the treatment of obesity.
Conditions Studied
Interventions
- DRUG Zonisamide SR placebo/ bupropion SR placebo
- DRUG Zonisamide SR placebo/ bupropion SR 360 mg/day
- DRUG Zonisamide SR 120 mg/day/ bupropion SR placebo
- DRUG Zonisamide SR 360 mg/day/ bupropion SR placebo
- DRUG Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day
Study Locations (20)
Massachusetts
- Nutrition and Weight Management Center, Boston Medical Center - Boston
- FutureCare Studies - Springfield
North Carolina
- Internal Medicine Associates of Charlotte - Charlotte
- Wake Research Associates, LLC - Raleigh
Alabama
- SelfCenter, PC - Fairhope
California
- Nutrition and Metabolic Research - La Jolla
Colorado
- Center for Human Nutrition/UCD - Denver
Florida
- Miami Research Associates - Miami
Georgia
- CSRA Partners in Health, Inc. - Augusta
Illinois
- Radiant Research, Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 729 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00709371
The ClinicalTrials.gov registry entry for NCT00709371 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 729 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (11% lower). The listed sponsor is Orexigen Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 5 interventions - of which Zonisamide SR placebo/ bupropion SR placebo is the first listed.
NCT00709371 reports 20 study locations spanning 18 distinct geographic areas - top geographies include Massachusetts, North Carolina, Alabama.
Frequently Asked Questions
What is clinical trial NCT00709371 about?
NCT00709371 is a clinical study titled "Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity". The purpose of this study is determine if the combination of zonisamide SR and bupropion SR are is more effective than either drug given alone or placebo in the treatment of obesity.
What is the current status of trial NCT00709371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 729 participants. The study started on 2008-07. Estimated completion is 2009-07.
What conditions does trial NCT00709371 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT00709371?
The interventions under investigation include: Zonisamide SR placebo/ bupropion SR placebo (DRUG), Zonisamide SR placebo/ bupropion SR 360 mg/day (DRUG), Zonisamide SR 120 mg/day/ bupropion SR placebo (DRUG), Zonisamide SR 360 mg/day/ bupropion SR placebo (DRUG), Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day (DRUG).
Who is sponsoring clinical trial NCT00709371?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00709371 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.